Comparative efficacy and safety of orally administered PCSK9 inhibitors in patients with Hypercholesterolaemia: a dose-stratified systematic review and network meta-analysis.
EndocrineOct 6, 2026 (epub)
Ahmed Talkhan, Mohamed Hamouda Elkasaby, Amr M Abou Elezz et al.
✦ AI-curated · Sources linked
In 30 seconds
This network meta-analysis evaluated the efficacy and safety of orally administered PCSK9 inhibitors in patients with hypercholesterolemia, analyzing five randomized trials with 4,227 participants. The study found that all drug-dose combinations significantly reduced LDL-C, with NNC0385-0434 100 mg showing a mean reduction of -61.8 percentage points compared to placebo. No short-term safety signals were detected.
Key findings
- NNC0385-0434 100 mg reduced LDL-C by -61.8 pp compared to placebo.
- MK-0616 30 mg resulted in a -60.9 pp reduction in LDL-C.
- All drug-dose combinations significantly lowered LDL-C levels.
- No short-term safety signals were identified in the trials.
Why it matters
The findings suggest that oral PCSK9 inhibitors could provide an effective alternative to injectable options for managing hypercholesterolemia, potentially improving patient adherence and access to treatment.